logo
Alert muted before teen died at unit, inquest told

Alert muted before teen died at unit, inquest told

Yahoo01-05-2025
Staff muted a safety alarm before a teenager was found unconscious at an NHS mental health unit, an inquest heard.
Elise Sebastian died in April 2021 after she was found unresponsive in her bedroom at the St Aubyn Centre in Colchester.
The 16-year-old was supposed to receive one-to-one care but an inquest was told an alert system, linked with her bedroom, was muted and she was left alone for 28 minutes.
The coroner was told changes had been made to the alert system.
The unit is run by the Essex Partnership University NHS Foundation Trust (EPUT), which is the subject of an ongoing public inquiry.
Elise, who was from Southminster near Maldon, was found unresponsive in her room on 17 April 2021.
She died in hospital two days later.
The alert system, called Oxyvision, was introduced in the ward two months beforehand.
The inquest was told the system was designed to help staff monitor the safety of patients in their bedrooms and bathrooms by using infrared sensors, and to reduce the number of self-harming incidents.
Essex area coroner Sonia Hayes read from a patient safety investigation conducted by EPUT following Elise's death.
It said that "confidence had been weakened" in the system because the wi-fi was not reliable on the mobile tablets used by staff.
An alarm would usually sound on the tablets if a patient was where they should not be.
The report also found an alert on a desktop computer in the nurse's office was muted.
It said this "led to a considerable reduction in the line of sight to Elise's bedroom".
The coroner was told it was the trust's policy to raise a Datix safety report if the wi-fi was not working properly, but no report could be found.
The inquest jury was told - that the day after she died - the trust changed its operating procedure, telling staff the volume on alerts must not be turned down or muted.
Laura Cozens is head of patient safety and quality at Oxyhealth, which provides the Oxyvision system.
She said the tablet software had since been tweaked, so that the volume of the alert automatically rose after 60 seconds of sounding.
The system was an "additional supportive tool and it shouldn't replace staff", she added.
Brian O'Donnell, clinical lead for EPUT, told the jury that signs had been placed around the main computer terminal asking staff not to turn down the alert volume.
He said warnings and alerts should never be ignored, adding he "would absolutely not expect any staff member to mute the volume".
Mr O'Donnell was asked if staff had muted it so they were not disturbed.
"I wasn't there, so I don't know," he added.
He admitted that since Oxyvision was installed, there had been some complacency.
"We do rely too much on technology nowadays," he said.
The inquest continues.
Follow Essex news on BBC Sounds, Facebook, Instagram and X.
NHS trust admits failures led to teenager's death
Essex Coroner's Service
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pharmacy warning of unsustainable demand for weight loss medication
Pharmacy warning of unsustainable demand for weight loss medication

Yahoo

time3 hours ago

  • Yahoo

Pharmacy warning of unsustainable demand for weight loss medication

The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'

Pharmacies warn of unsustainable demand for weight loss medication
Pharmacies warn of unsustainable demand for weight loss medication

Yahoo

time3 hours ago

  • Yahoo

Pharmacies warn of unsustainable demand for weight loss medication

The booming demand for weight loss jabs may be unsustainable, pharmacists warn. Many more patients are interested in using weight loss medication than are actually suitable for treatment, according to the National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies. Some 21% of people who were interviewed in a NPA-commissioned poll agreed they had attempted to access weight loss treatments in the last year, either online or in person at a pharmacy, rising to 35% of 16 to 34-year-olds. This is compared to only 7% of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'

Pharmacy warning of unsustainable demand for weight loss medication
Pharmacy warning of unsustainable demand for weight loss medication

Yahoo

time5 hours ago

  • Yahoo

Pharmacy warning of unsustainable demand for weight loss medication

The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store